Ersözlü, Ersin ; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences > Memory clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center ; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association
Preis, Lukas; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences > Memory clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center ; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association
Arslan, Orkan; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences > Memory clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center ; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association
Gref, Daria; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences, > Memory Clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center, ; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association
Droste, Louise; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences > Memory clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center ; German Center for Neurodegenerative Diseases (DZNE)
Hellmann-Regen, Julian; Charité - Universitätsmedizin Berlin > Department of Psychiatry and Neurosciences > Memory Clinic ; Charité - Universitätsmedizin Berlin > ECRC Experimental and Clinical Research Center ; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association
Language :
English
Title :
An exploratory analysis of plasma biomarkers associated with cerebral amyloid angiopathy
Attems, J., Jellinger, K.A., Lintner, F., 2005. Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. 110, 222–231. https://doi.org/10.1007/s00401-005-1064-y
Bechmann, I., Lossau, S., Steiner, B., Mor, G., Gimsa, U., Nitsch, R., 2000. Reactive astrocytes upregulate Fas (CD95) and Fas ligand (CD95L) expression but do not undergo programmed cell death during the course of anterograde degeneration. Glia 32, 25–41. https://doi.org/10.1002/1098-1136(200010)32:1%253C25::aid-glia30%253E3.0.co;2-y
Chai, Y.L., Chong, J.R., Raquib, A.R., Xu, X., Hilal, S., Venketasubramanian, N., Tan, B.Y., Kumar, A.P., Sethi, G., Chen, C.P., Lai, M.K.P., 2021. Plasma osteopontin as a biomarker of Alzheimer’s disease and vascular cognitive impairment. Sci. Rep. 11, 4010. https://doi.org/10.1038/s41598-021-83601-6
Charidimou, A., Boulouis, G., Frosch, M.P., Baron, J.-C., Pasi, M., Albucher, J.F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., Calviere, L., Caparros, F., Casolla, B., Cordonnier, C., Delisle, M.-B., Deramecourt, V., Dichgans, M., Gokcal, E., Herms, J., Hernandez-Guillamon, M., Jäger, H.R., Jaunmuktane, Z., Linn, J., Martinez-Ramirez, S., Martínez-Sáez, E., Mawrin, C., Montaner, J., Moulin, S., Olivot, J.-M., Piazza, F., Puy, L., Raposo, N., Rodrigues, M.A., Roeber, S., Romero, J.R., Samarasekera, N., Schneider, J.A., Schreiber, S., Schreiber, F., Schwall, C., Smith, C., Szalardy, L., Varlet, P., Viguier, A., Wardlaw, J.M., Warren, A., Wollenweber, F.A., Zedde, M., van Buchem, M.A., Gurol, M.E., Viswanathan, A., Al-Shahi Salman, R., Smith, E.E., Werring, D.J., Greenberg, S.M., 2022. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 21, 714–725. https://doi.org/10.1016/S1474-4422(22)00208-3
Choi, C., Benveniste, E.N., 2004. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res. Brain Res. Rev. 44, 65–81.
Cozza, M., Amadori, L., Boccardi, V., 2023. Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment. J. Neurol. Sci. 454, 120866. https://doi.org/10.1016/j.jns.2023.120866
Cummings, J., Gold, M., Mintun, M., Irizarry, M., von Eschenbach, A., Hendrix, S., Berry, D., Sampaio, C., Sink, K., Landen, J., Kivipelto, M., Grundman, M., Arnold, S.E., Green, A., Partrick, K., Nisenbaum, L., Burstein, A., Fillit, H., n.d. Key Considerations for Combination Therapy in Alzheimer’s Clinical Trials: Perspectives from an Expert Advisory Board Convened by the Alzheimer’s Drug Discovery Foundation. .
Endo, Y., Hasegawa, K., Nomura, R., Arishima, H., Kikuta, K.-I., Yamashita, T., Inoue, Y., Ueda, M., Ando, Y., Wilson, M.R., Hamano, T., Nakamoto, Y., Naiki, H., 2019. Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy. Acta Neuropathol. Commun. 7, 12. https://doi.org/10.1186/s40478-019-0662-1
Foster, E.M., Dangla-Valls, A., Lovestone, S., Ribe, E.M., Buckley, N.J., 2019. Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front. Neurosci. 13, 164. https://doi.org/10.3389/fnins.2019.00164
Graff-Radford, J., Yong, K.X.X., Apostolova, L.G., Bouwman, F.H., Carrillo, M., Dickerson, B.C., Rabinovici, G.D., Schott, J.M., Jones, D.T., Murray, M.E., 2021. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 20, 222–234. https://doi.org/10.1016/S1474-4422(20)30440-3
Grand Moursel, L., van der Graaf, L.M., Bulk, M., van Roon-Mom, W.M.C., van der Weerd, L., 2019. Osteopontin and phospho-SMAD2/3 are associated with calcification of vessels in D-CAA, an hereditary cerebral amyloid angiopathy. Brain Pathol. 29, 793–802. https://doi.org/10.1111/bpa.12721
Hampel, H., Elhage, A., Cho, M., Apostolova, L.G., Nicoll, J.A.R., Atri, A., 2023. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146, 4414–4424. https://doi.org/10.1093/brain/awad188
Huang, Y., Happonen, K.E., Burrola, P.G., O’Connor, C., Hah, N., Huang, L., Nimmerjahn, A., Lemke, G., 2021. Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat. Immunol. 22, 586–594. https://doi.org/10.1038/s41590-021-00913-5
Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., 2012. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers. Dement. 8, 1–13. https://doi.org/10.1016/j.jalz.2011.10.007
Jäkel, L., De Kort, A.M., Klijn, C.J.M., Schreuder, F.H.B.M., Verbeek, M.M., 2022. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers. Dement. 18, 10–28. https://doi.org/10.1002/alz.12366
Knudsen, K.A., Rosand, J., Karluk, D., Greenberg, S.M., 2001. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56, 537–539. https://doi.org/10.1212/wnl.56.4.537
Leitner, D., Kavanagh, T., Kanshin, E., Balcomb, K., Pires, G., Thierry, M., Suazo, J.I., Schneider, J., Ueberheide, B., Drummond, E., Wisniewski, T., 2024. Differences in the cerebral amyloid angiopathy proteome in Alzheimer’s disease and mild cognitive impairment. Acta Neuropathol. 148, 9. https://doi.org/10.1007/s00401-024-02767-1
Love, S., Chalmers, K., Ince, P., Esiri, M., Attems, J., Jellinger, K., Yamada, M., McCarron, M., Minett, T., Matthews, F., Greenberg, S., Mann, D., Kehoe, P.G., 2014. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am. J. Neurodegener. Dis. 3, 19–32.
Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V.M.-Y., Trojanowski, J.Q., Alzheimer’s Disease Neuroimaging Initiative, 2009. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol. 65, 403–413. https://doi.org/10.1002/ana.21610
Su, J.H., Anderson, A.J., Cribbs, D.H., Tu, C., Tong, L., Kesslack, P., Cotman, C.W., 2003. Fas and Fas Ligand are associated with neuritic degeneration in the AD brain and participate in β-amyloid-induced neuronal death. Neurobiol. Dis. 12, 182–193. https://doi.org/10.1016/s0969-9961(02)00019-0
Switzer, A.R., Charidimou, A., McCarter, S., Vemuri, P., Nguyen, A.T., Przybelski, S.A., Lesnick, T.G., Rabinstein, A.A., Brown, R.D., Knopman, D.S., Petersen, R.C., Jack, C.R., Jr, Reichard, R.R., Graff-Radford, J., 2024. Boston criteria v2.0 for cerebral amyloid angiopathy without hemorrhage: An MRI-neuropathologic validation study. Neurology 102, e209386. https://doi.org/10.1212/WNL.0000000000209386
Theodorou, A., Tsantzali, I., Kapaki, E., Constantinides, V.C., Voumvourakis, K., Tsivgoulis, G., Paraskevas, G.P., 2021. Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review. Cereb. Circ. Cogn. Behav. 2, 100010. https://doi.org/10.1016/j.cccb.2021.100010
Vidoni, E.D., Yeh, H.-W., Morris, J.K., Newell, K.L., Alqahtani, A., Burns, N.C., Burns, J.M., Billinger, S.A., 2016. Cerebral β-amyloid angiopathy is associated with earlier dementia onset in Alzheimer’s disease. Neurodegener. Dis. 16, 218–224. https://doi.org/10.1159/000441919
Weller, R.O., Subash, M., Preston, S.D., Mazanti, I., Carare, R.O., 2008. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 18, 253–266. https://doi.org/10.1111/j.1750-3639.2008.00133.x
Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S.J., Schmit, D., Kramann, R., Körbel, C., Ampofo, E., Laschke, M.W., Selejan, S.-R., Paschen, A., Herter, T., Schuster, S., Silbernagel, G., Sester, M., Sester, U., Aßmann, G., Bals, R., Kostner, G., Jahnen-Dechent, W., Menger, M.D., Rohrer, L., März, W., Böhm, M., Jankowski, J., Kopf, M., Latz, E., Niemeyer, B.A., Fliser, D., Laufs, U., Speer, T., 2020. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat. Immunol. 21, 30–41. https://doi.org/10.1038/s41590-019-0548-1
